Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort

Extended circulating tumor DNA (ctDNA) sequencing to optimize the selection between anti-EGFR rechallenge and other later lines in patients with RAS/BRAF wild-type metastatic colorectal cancer

- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy